Tech Company Financing Transactions

Synakis Funding Round

Synakis, based in Toronto, ON, secured $1.9 million in funding from Chiefswood Holdings, Toronto Innovation Acceleration Partners and Kickstart Ventures.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

160 College Street 510
Toronto, ON, M5S 3E1
Canada

Phone

Undisclosed

Website

www.synakis.ca

Email Address

[email protected]

Overview

Synakis is a pre-clinical biotech startup developing breakthrough biomaterial-based treatments for ocular diseases, including retinal detachment, glaucoma, and retinal degenerative diseases. Our mission is to restore vision and enhance the quality of life for patients. Synakis' core technology, SNK-125, is a proprietary hydrogel specifically designed for ocular delivery. SNK-125 is injectable, biocompatible, biodegradable, non-swelling and transparent. We are developing it as a vitreous replacement for retinal surgery and to deliver engineered therapeutics to treat leading causes of blindness.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Thierry Nivaggioli

        

Chief Marketing Officer

Robert Devenyi

        

Chief Scientific Officer

Molly Shoichet

        

VP - Operations

Jonathan Labriola

        

VP - R & D

Adam Forman

        

Browse more venture capital transactions:

Prev: 5/25/2026: Lucra Sports venture capital transaction
Next: 5/25/2026: OneReg venture capital transaction

Share this article

About Our VC Transactions Data

Our team works diligently to report on all VC transactions involving tech companies. All VC database entries on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary